BeOne Medicines AG
ONCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company carries a $42.96B market cap, placing it firmly in the large-cap category. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Market Cap
$42.96B
Beta
0.61
P/E (TTM)
67.55
P/E (Fwd)
36.15
EPS (TTM)
$5.59
EPS (Fwd)
$10.45
ROE
14.7%
ROA
7.5%
Cash
$5.10B
Total Debt
$2.05B
Free CF
$879.0M
52W Change
19.7%
Annual Financials
Cash vs Debt
Where ONC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ONC finished 15.84% above its 150-day moving average ($319.55) and 14.65% above its 200-day moving average ($322.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ONC overbought or oversold?
At the October 20, 2026 close, ONC's RSI(14) was 53.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $5.10B in cash comfortably exceeding the $2.05B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $879.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 14.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.42B (2022) to $5.34B (2025), reflecting a 277% increase over the period.
The relatively low beta of 0.61 suggests ONC is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, ONC has financial flexibility that may help navigate uncertain periods. At over 50x earnings, ONC carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ONC.